<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047513</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-PAK-0313</org_study_id>
    <secondary_id>2013-005559-34</secondary_id>
    <secondary_id>AX_CL_PANC_AIO_003710</secondary_id>
    <nct_id>NCT02047513</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer</brief_title>
  <acronym>NEONAX</acronym>
  <official_title>Neoadjuvant Plus Adjuvant or Only Adjuvant Nab-Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer: A Prospective, Randomized, Controlled, Phase II Study of the AIO (Working Group for Medical Oncology From the German Cancer Society) Pancreatic Cancer Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NEONAX is an interventional, prospective, randomized, controlled, open label, two sided&#xD;
      survival phase II studies against a fixed survival probability, with an unconnected analysis&#xD;
      of the results in both experimental arms.&#xD;
&#xD;
      Determining the impact of 2 cycles of Perioperative nab-paclitaxel/gemcitabine followed by&#xD;
      surgery and 4 cycles of adjuvant nab-paclitaxel/gemcitabine or 6 cycles of adjuvant&#xD;
      nab-paclitaxel/gemcitabine on the Disease free survival (DFS) rate at 18 months post&#xD;
      randomization&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned trial will enable us to address the following issues:&#xD;
&#xD;
        -  Identification of patients who benefit from surgery. Tumor progress during intensified&#xD;
           Perioperative chemotherapy is likely to indicate a particularly poor prognosis&#xD;
           suggesting that these patients would not have benefitted from immediate surgery.&#xD;
&#xD;
        -  Assess tumor response/downsizing using nab-paclitaxel/gemcitabine also at the molecular&#xD;
           level&#xD;
&#xD;
        -  Can we achieve a better systemic tumor control or reduce the metastatic spread using&#xD;
           nab-paclitaxel/gemcitabine compared to adjuvant gemcitabine&#xD;
&#xD;
        -  Examining the effect of a more efficacious chemotherapy regimen&#xD;
           (nab-paclitaxel/gemcitabine) in the adjuvant setting&#xD;
&#xD;
        -  Defining the impact of a perioperative or adjuvant chemotherapy with&#xD;
           gemcitabine/nab-paclitaxel on DFS and 3-year Overall survival (OS)&#xD;
&#xD;
      Histopathological tumor regression will be evaluated in addition to tumor size measurement&#xD;
      according to Response Evaluation Criteria In Solid Tumors (RECIST). We will establish a&#xD;
      histopathological tumor regression score to evaluate the efficacy of the neoadjuvant&#xD;
      treatment. For this score we will examine tumor core biopsies obtained prior to neoadjuvant&#xD;
      treatment and histological tumor specimen after surgery in both arms.&#xD;
&#xD;
      To reliably determine R0 resections, the resected specimen will be prepared for pathology in&#xD;
      a defined manner according to the procedure set out in the German S3 guidelines for&#xD;
      pancreatic cancer.&#xD;
&#xD;
      This trial provides the unique opportunity in pancreatic cancer to obtain material prior to&#xD;
      and after surgery for biomarker analysis and correlation with outcome. We will perform&#xD;
      pharmacogenomic candidate gene analysis of hENT1 (human equilibrative nucleoside&#xD;
      transporter-1), CDA (cell differentiation agent), DCK (Desoxycytidin-Kinase) and&#xD;
      5´nucleotidase in both arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Disease free survival (DFS)</measure>
    <time_frame>18 months after randomization</time_frame>
    <description>To improve the DFS rate at 18 months in at least one arm to≥ 55%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>57 months</time_frame>
    <description>• Safety of nab-paclitaxel/gemcitabine in the neoadjuvant and adjuvant setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morbidity and mortality</measure>
    <time_frame>7 years</time_frame>
    <description>• pre- and postoperative morbidity and mortality in both studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>57 months</time_frame>
    <description>• Dropout rate due to toxicity in the neoadjuvant study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>7 years</time_frame>
    <description>• Disease progression during neoadjuvant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resection rate</measure>
    <time_frame>53 months</time_frame>
    <description>• R0 and R1 resection rate in both groups as assessed according to the German S3 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>57 months</time_frame>
    <description>• Tumor response according to RECIST v1.1; histopathological regression based on a predefined pathological handling of the resected specimen in the perioperative study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of tumor regression and R0 resection</measure>
    <time_frame>57 months</time_frame>
    <description>• Correlation of tumor regression and R0 resection rate with response according to RECIST v1.1 in the perioperative study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>7 years</time_frame>
    <description>• Overall survival in both studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor recurrence</measure>
    <time_frame>7 years</time_frame>
    <description>• First site of tumor recurrence in both studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>57 months</time_frame>
    <description>• Explorative analysis of health related quality of life in both studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacogenomic markers, tumor-biomarkers and molecular analyses</measure>
    <time_frame>57 months</time_frame>
    <description>• Correlation of DFS, OS and tumor regression with pharmacogenomic markers, tumor-biomarkers and molecular analyses in both studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>57 months</time_frame>
    <description>• Assessment of safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>66 months</time_frame>
    <description>To assess tumor response using the imaging data (CT scans, MRI-scans) obtained during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor recurrence</measure>
    <time_frame>66 months</time_frame>
    <description>To assess tumor recurrence using the imaging data (CT scans, MRI-scans) obtained during the trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Resectable Pancreatic Cancer</condition>
  <condition>Ductal Adenocarcinoma of the Pancreas</condition>
  <arm_group>
    <arm_group_label>perioperative nab-paclitaxel/gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant nab-paclitaxel/gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perioperative nab-paclitaxel/gemcitabine</intervention_name>
    <description>2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)</description>
    <arm_group_label>perioperative nab-paclitaxel/gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant nab-paclitaxel/gemcitabine</intervention_name>
    <description>Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)</description>
    <arm_group_label>adjuvant nab-paclitaxel/gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytological confirmed, clearly resectable ductal adenocarcinoma of&#xD;
             the pancreas (PDAC) ≤ cT3 with no prior tumor specific treatment.&#xD;
&#xD;
          -  No evidence of metastases to distant organs (e.g. liver, peritoneum, lung).&#xD;
&#xD;
          -  Resectable tumor. Determination of resectability based on spiral CT scans with both&#xD;
             oral and i.v. contrast enhancement or on MRI using a recent consensus definition&#xD;
             (Resectability: Clear fat planes around the celiac artery, hepatic artery and superior&#xD;
             mesenteric artery.)&#xD;
&#xD;
          -  Measurable tumor according to RECIST 1.1&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 ml/min&#xD;
&#xD;
          -  Serum total bilirubin level ≤ 2.5 x ULN (not necessary for enrollment or&#xD;
             randomization, but before start of neoadjuvant chemotherapy in arm A)&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 x ULN (not necessary for enrollment or randomization, but before&#xD;
             start of neoadjuvant chemotherapy in arm A)&#xD;
&#xD;
          -  In case of biliary obstruction, biliary decompression is required if the patient was&#xD;
             randomized to receive neoadjuvant chemotherapy (arm A)&#xD;
&#xD;
          -  White blood cell count ≥ 3.5 x 106/ml, neutrophil granulocytes count ≥ 1,5 x 106/ml,&#xD;
             platelet count ≥ 100 x 106/ml&#xD;
&#xD;
          -  Signed informed consent incl. participation in translational research&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Borderline resectable PDAC by radiologic criteria&#xD;
&#xD;
          -  Papillary cancer&#xD;
&#xD;
          -  Neuroendocrine Cancer&#xD;
&#xD;
          -  Tumor specific pre-treatment&#xD;
&#xD;
          -  Local recurrence&#xD;
&#xD;
          -  Peritoneal or other distant metastases&#xD;
&#xD;
          -  Radiographic evidence of severe portal hypertension/cavernous transformation&#xD;
&#xD;
          -  Infiltration of extrapancreatic organs (except duodenum)&#xD;
&#xD;
          -  Ascites&#xD;
&#xD;
          -  Gastric outlet obstruction&#xD;
&#xD;
          -  Global respiratory insufficiency requiring oxygen supplementation&#xD;
&#xD;
          -  Chronic infectious diseases, immune deficiency syndromes&#xD;
&#xD;
          -  Premalignant hematologic disorders, e.g. myelodysplastic syndrome&#xD;
&#xD;
          -  Disability to understand and sign written informed consent document&#xD;
&#xD;
          -  Past or current history of malignancies except for the indication under this study and&#xD;
             curatively treated:&#xD;
&#xD;
               -  Basal and squamous cell carcinoma of the skin&#xD;
&#xD;
               -  In-situ carcinoma of the cervix&#xD;
&#xD;
               -  Other malignant disease without recurrence after at least 2 years of follow-up&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (incl. myocardial infarction, unstable&#xD;
             angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia)&#xD;
             6 months before enrollment&#xD;
&#xD;
          -  Clinically relevant or history of interstitial lung disease, e.g. non-infectious&#xD;
             pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline&#xD;
             chest CT scan or chest x-ray.&#xD;
&#xD;
          -  History of or evidence upon physical examination of CNS disease unless adequately&#xD;
             treated (e.g. primary brain tumor, seizure not controlled with standard medical&#xD;
             therapy or history of stroke).&#xD;
&#xD;
          -  Pre-existing neuropathy &gt; grade 1 (NCI CTCAE)&#xD;
&#xD;
          -  Allogeneic transplantation requiring immunosuppressive therapy or other major&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Severe non-healing wounds, ulcers or bone fractions&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Patients not receiving therapeutic anticoagulation must have an INR &lt; 1.5 ULN and PTT&#xD;
             &lt; 1.5 ULN within 28 days prior to randomization. The use of full dose anticoagulants&#xD;
             is allowed as long as the INR or PTT is within therapeutic limits (according to the&#xD;
             medical standard in the institution)&#xD;
&#xD;
          -  Major surgical procedures, except open biopsy, nor significant traumatic injury within&#xD;
             28 days prior to randomization, or anticipation of the need for major surgical&#xD;
             procedure during the course of the study except for surgery of pancreatic cancer with&#xD;
             curative intent and central intravenous line placement for chemotherapy&#xD;
             administration.&#xD;
&#xD;
          -  Pregnancy or breastfeeding women.&#xD;
&#xD;
          -  Subjects with known allergies to the study drugs or to any of its excipients.&#xD;
&#xD;
          -  Current or recent (within the 28 days prior randomization) treatment with another&#xD;
             investigational drug or participation in another investigational study.&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             compromising compliance with the study protocol and the follow-up schedule; those&#xD;
             conditions should be discussed with the patient prior to registration in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Seufferlein, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm, Dept. of Internal Medicine I</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Ulm, Dept. of Internal Medicine I</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>AIO - Working Group for Medical Oncology from the German Cancer Society</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

